Page 2 of 5
12345

2021 (12 POSTS)

Dougherty C, Friedman BW, Aurora S, Bariahtaris S, Shrewsbury S, Baker-Wagner M, Sacks N, Kautz S, Cyr P. Impact of INP104 on healthcare resource use among patients in STOP 301. Presentation at American Academy of Neurology Annual Meeting, Virtual, April 2021.

Dougherty C, Friedman BW, Aurora S, Bariahtaris S, Shrewsbury S, Baker-Wagner M, Sacks N, Kautz S, Cyr P. INP104 reduces self-reported ED and urgent care in patients with episodic migraine. Presentation at Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Virtual, April 2021.

Sacks NC, Healey B, Cyr PL, Slocomb T, James E, Beggs A, Graham RJ. Healthcare resource use and expenditures in patients with x-linked myotubular myopathy (XLMTM). Poster presentation, ISPOR 25th Annual International Meeting, Orlando, FL, April 2021.

Chew D, Sacks NC, Emden MR, Preib MT, Cyr PL, Wood D, Pokorney SD. 2021. Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States. Am Heart J 233(March):132–140; doi: 10.1016/j.ahj.2020.12.012. PMID: 33359780.

View Abstract

Dean R, Jensen IS, Cyr PL, Miller B, Maru B, Sproule DM, Feltner DE, et al. 2021. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Pol 9(1):1889841; doi: 10.1080/20016689.2021.1889841. PMID: 33708361.

View Abstract

2020 (8 POSTS)

Dean R, Arjunji R, Awano H, Igarash A, Tanaka A, Jensen IS, Cyr PL et al. Cost-effectiveness of onasemnogene abeparvocec (ZOLGENSMA) for spinal muscular atrophy type 1 against nusinersen in Japan. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Sacks NC, Healey B, Cyr PL, Graham R. Economic burden of X-linked myotubular myopathy (XLMTM) by ventilation status. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Miller B, Jensen IS, Dean R, Cyr PL, Slocomb T, James E, Beggs AH. Health resource use in patients with x-linked myotubular myopathy (XLMTM): Data from the RECENSUS Study. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Miller B, Yao W, Dean R, Jensen I, Cyr PL, Slocomb T. Understanding the impact of XLMTM on parents and caregivers in the US: An analysis of survey results. ISPOR 18th Annual European Meeting, Milan Italy, 2020.

Sacks NC, Everson K, Emden MR, Cyr PL, Wood DR, Raza S, Wood KA, Pokorney SD. 2020. Disparities in the management of newly diagnosed paroxysmal supraventricular tachycardia for women versus men in the United States. J Am Heart Assoc 9(19):e015910; doi: 10.1161/JAHA.120.0159. PMID: 32954896.

View Abstract

Sacks NC, Healey B, Cyr PL, Batt K, Henig NR. The economic burden of bronchiolitis obliterans syndrome (BOS) in allogenic hematopoietic stem cell transplant (alloHSCT) patients with Medicare coverage. Poster presentation, ISPOR 25th Annual International Meeting, Orlando, FL, May 2020.

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362. PMID: 32341772.

View Abstract

Sacks NC, Cyr PL, Preib MT, Everson K, Wood DR, Raza S, Pokorney SD. 2020. Healthcare resource use and expenditures in patients newly diagnosed with paroxysmal supraventricular tachycardia. Am J Cardiol 125(2):215–221; doi: 10.1016/j.amjcard.2019.10.015. PMID: 31771758.

View Abstract

2019 (11 POSTS)

Sacks NC, Cyr PL, Green S, Healey B, Preib M, Wood D, Pokorney S. Prevalence of patients with paroxysmal supraventricular tachycardia (PSVT) in the United States. Poster presentation, European Society for Cardiology Congress, Paris, France, September 2019.

Sacks NC, Everson K, Cyr PL, Preib M, Wood D, Pokorney S. Healthcare resource use and expenditures in patients newly diagnosed with paroxysmal supraventricular tachycardia (PSVT) in the United States. Podium presentation, International Society for Pharmacoepidemiology Annual Meetings, Philadelphia, PA, August 2019.

Sacks NC, Cyr PL, Green S, Wood D, Pokorney S. Healthcare resource use and costs following catheter ablation in paroxysmal supraventricular tachycardia (PSVT) patients age <65. Podium presentation, International Society for Pharmacoeconomics and Outcomes Research. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, New Orleans, May 2019.

Hathway J, Jensen IS, Cyr PL, Koshy, TI, Parks, P, Weinstein MC. Economic analysis of colorectal cancer screening from multiple stakeholder perspectives: Key components to improve practical applications in the US. ISPOR 24th Annual International Meeting, New Orleans LA, 2019.

Sacks NC, Everson K, Cyr PL, Emden M, Preib M, Wood D, Pokorney S. Variations in healthcare resource use and expenditures by age in patients under Age 65 newly diagnosed with paroxysmal supraventricular tachycardia (PSVT) in the United States. ISPOR 24th Annual International Meeting, New Orleans LA, 2019.

Sacks NC, Cyr PL, Green S, Wood D, Pokorney S. Healthcare resource use and costs following catheter ablation in paroxysmal supraventricular tachycardia (PSVT) patients age <65. Podium presentation, International Society for Pharmacoeconomics and Outcomes Research. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, New Orleans, May 2019.

Sacks NC, Sharma A, Cyr PL, Stong L, Dahdal DN. Real-world evidence comparison of colorectal cancer screening outcomes with different colorectal cancer preparation agents in adults 65 years and older. Digestive Disease Week Annual Meeting, San Diego, May 2019.

Page 2 of 5
12345